论文部分内容阅读
2例肿瘤患者口服优福定(UFT)4片,其血清FT-207浓度及药代学参数存在明显个体差异。124只肝癌腹水型实体瘤小鼠服用UFT50、40和31mg/kg/d×8d,最低稳态血药浓度亦有相似的个体差异。将荷瘤鼠按血清FT-207浓度分组,其血药浓度与T/C值和第3、6、8天的体重增长率均显著相关,相关系数r分别为-0.9557(P<0.0005)、-0.8936(P<0.005)、-0.9795(P<0.Q005)和-0.9770(P<0.0005)。使T/C值为50％或实验始末维持体重不变的FT-207浓度分别为3.03和3.09μg/ml。文中讨论了监测血清FT-207浓度的必要性及其临床意义。
Two patients with oral tumor of UF (UFT) 4, the serum FT-207 concentration and pharmacokinetic parameters were significantly individual differences. 124 hepatocellular carcinoma ascites solid tumor mice taking UFT50, 40 and 31mg / kg / d × 8d, the lowest steady-state plasma concentrations also have similar individual differences. The tumor-bearing mice were grouped according to the concentration of FT-207 in serum, and the plasma concentration was significantly correlated with the T / C value and the weight gain rate on the 3rd, 6th and 8th day. The correlation coefficients r were -0.9557 (P <0.0005) -0.8936 (P <0.005), -0.9795 (P <0.Q005) and -0.9770 (P <0.0005). The concentrations of FT-207 with a T / C value of 50% or unchanged body weight at the end of the experiment were 3.03 and 3.09 μg / ml, respectively. The paper discusses the need for monitoring serum FT-207 concentration and its clinical significance.